Henry Schein, Inc. (NASDAQ:HSIC) Short Interest Up 28.9% in March

Henry Schein, Inc. (NASDAQ:HSIC) was the recipient of a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 5,374,661 shares, an increase of 28.9% from the February 26th total of 4,168,764 shares. Based on an average daily volume of 1,379,464 shares, the short-interest ratio is presently 3.9 days. Approximately 4.7% of the shares of the stock are short sold.

Henry Schein Trading Up 0.8%

Shares of Henry Schein stock traded up $0.60 on Monday, hitting $72.70. The stock had a trading volume of 941,799 shares, compared to its average volume of 1,276,042. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. Henry Schein has a one year low of $60.56 and a one year high of $89.29. The stock has a market cap of $8.34 billion, a price-to-earnings ratio of 22.23, a PEG ratio of 2.13 and a beta of 0.87. The stock’s 50-day simple moving average is $77.22 and its two-hundred day simple moving average is $73.28.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. The company had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm’s revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts predict that Henry Schein will post 4.74 EPS for the current year.

Insider Activity

In related news, Director Philip A. Laskawy sold 2,844 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $80.36, for a total value of $228,543.84. Following the completion of the sale, the director owned 21,961 shares in the company, valued at $1,764,785.96. The trade was a 11.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kurt P. Kuehn sold 2,844 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the completion of the sale, the director directly owned 15,420 shares of the company’s stock, valued at approximately $1,217,563.20. This represents a 15.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 105,911 shares of company stock valued at $8,574,982. 1.14% of the stock is owned by insiders.

Institutional Trading of Henry Schein

A number of institutional investors have recently modified their holdings of the company. CYBER HORNET ETFs LLC purchased a new position in shares of Henry Schein in the 2nd quarter valued at approximately $25,000. MUFG Securities EMEA plc purchased a new stake in Henry Schein in the second quarter worth $27,000. Flagship Harbor Advisors LLC purchased a new stake in Henry Schein in the fourth quarter worth $30,000. Federated Hermes Inc. bought a new position in Henry Schein in the fourth quarter worth $32,000. Finally, Los Angeles Capital Management LLC bought a new position in Henry Schein in the fourth quarter worth $37,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HSIC has been the subject of a number of recent research reports. Barrington Research set a $97.00 price objective on shares of Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, February 25th. UBS Group increased their target price on shares of Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Wells Fargo & Company lifted their target price on shares of Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Robert W. Baird set a $100.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research note on Monday, February 23rd. Finally, Morgan Stanley upped their price target on shares of Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a research report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $85.58.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.